Enterprise Value

396.2B

Cash

22.93B

Avg Qtr Burn

N/A

Short % of Float

0.46%

Insider Ownership

0.09%

Institutional Own.

71.30%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BALVERSA (erdafitinib) Details
Cancer, Urothelial cancer

Approved

Quarterly sales

TALVEY (talquetamab) Details
Cancer, Multiple myeloma

Approved

Quarterly sales

Approved

Quarterly sales

AKEEGA (niraparib/abiraterone) Details
Cancer, Castration-resistant prostate cancer

Approved

Quarterly sales

SPRAVATO (esketamine) Details
Treatment Resistant Depression

Approved

Quarterly sales

Approved

Quarterly sales

IMBRUVICA (ibrutinib) Details
Chronic lymphocytic leukemia

Approved

Quarterly sales

UPTRAVI (selexipag) Details
Pulmonary arterial hypertension

Approved

Quarterly sales

OPSUMIT (macitentan) Details
Pulmonary arterial hypertension

Approved

Quarterly sales

DARZALEX (daratumumab) Details
Cancer, Multiple myeloma

Approved

Quarterly sales

Approved

Quarterly sales

RYBREVANT (amivantamab) Details
Non-small cell lung carcinoma, Cancer

BLA

Acceptance for review

BLA

Acceptance for review

OPSUMIT (macitentan) w/tadalafil FDC Details
Pulmonary arterial hypertension

NDA

Submission

Phase 3

Data readout

RYBREVANT (amivantamab) Details
Cancer, Non-small cell lung carcinoma

Phase 3

Update

Phase 3

Update

Nipocalimab​ Details
Myasthenia gravis, Autoimmune disease

Phase 3

Update

TAR-200 (RIS/gemcitabine plus cetrelimab) Details
Cancer, Non-muscle invasive bladder cancer

Phase 2b

Data readout

Nipocalimab​ Details
Autoimmune disease, Sjögren-Larsson Syndrome

Phase 2

Update

Phase 2

Update

nipocalimab​ Details
Warm autoimmune hemolytic anemia

Phase 2

Update

nipocalimab​ Details
Rheumatoid arthritis

Phase 2a

Data readout

TAR-210 (RIS/erdafitinib) Details
Cancer, Non-muscle invasive bladder cancer

Phase 1

Data readout

IMBRUVICA (ibrutinib) Details
Lymphoma, Mantle cell lymphoma, Marginal zone lymphoma

Failed

Discontinued